Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
Immunocore reported updated Phase 1/2 brenetafusp data in heavily pretreated HLA-A*02:01-positive advanced melanoma at ASCO 2026. In 66 monotherapy patients, 6-month OS was 87% and disease control rate 52% (ORR 12%); median OS was 14.3 months. The company said results supported a 160 mcg dose for Phase 3 PRISM-MEL-301 and that safety was generally well tolerated.
How this was made
The 30-second read
Why it matters
The updated Phase 1/2 poster adds specific efficacy endpoints (landmark OS, DCR, ORR) in heavily pretreated patients and supports selecting 160 mcg for Phase 3, including a subgroup with primary PD-1 resistance. This can shift probability-weighted valuation for the Phase 3 program and improve investor confidence in the dose/combination strategy.
Market read
A concrete clinical datapoint plus a development decision (160 mcg selection) is a direct catalyst for IMCR’s melanoma program narrative at ASCO.
What to watch
CRS and lymphocyte count decreases were common (though attenuated); investors may focus on whether combination regimens replicate monotherapy tolerability and on the control-arm comparator in PRISM-MEL-301.
Background
Immunocore’s brenetafusp is an ImmTAC (TCR-bispecific) PRAME-targeted therapy for HLA-A*02:01-positive advanced melanoma, evaluated after anti–PD-(L)1 failure; PRISM-MEL-301 is the ongoing Phase 3 first-line registrational trial.
Ticker impact
Immunocore reported updated Phase 1/2 brenetafusp melanoma data and selected the 160 mcg dose for its Phase 3 PRISM-MEL-301 trial.
Near-term upside bias as investors re-rate brenetafusp’s clinical signal and Phase 3 probability of success; magnitude likely tempered by early-stage nature.
The article provides fresh clinical datapoints (6-month OS 87%, DCR 52%, median OS ~14.3 months) and a concrete development decision (160 mcg selection) tied to an ongoing registrational Phase 3.
Market effects
Reinforces ImmTAC platform credibility (T-cell fitness/IL7 biology) and may lift sentiment toward other T-cell redirecting oncology assets.
Primarily US biotech sentiment via Nasdaq-listed IMCR; limited direct regional spillover beyond oncology investors.
ASCO presentation can influence global clinical expectations for HLA-A*02:01/PRAME-targeted strategies and post–PD-1 options.
Counterpoint
Phase 1/2 results in a small, biomarker-selected cohort may overstate Phase 3 odds; efficacy in primary PD-1 resistance remains exploratory and numerically based.
Key entities
- drugBrenetafusp
PRAME-targeted ImmTAC therapy; updated Phase 1/2 data in heavily pretreated advanced melanoma and dose selection for Phase 3.
- clinical_trialPRISM-MEL-301 (NCT06112314)
Phase 3 trial randomizing brenetafusp 160 mcg + nivolumab vs nivolumab or nivolumab + relatlimab in first-line advanced cutaneous melanoma.
- science_updateIL7 / T cell fitness poster (ASCO 2026)
Preclinical/in vitro and patient data suggesting IL7 may enhance ImmTAC-mediated killing via improved T-cell fitness.
